Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) previous close was $5.21 while the outstanding shares total 35.17M. The firm has a beta of 2.72. ADMS’s shares traded lower over the last trading session, losing -1.73% on 06/03/21. The shares fell to a low of $5.06 before closing at $5.12. Intraday shares traded counted 0.61 million, which was -63.95% lower than its 30-day average trading volume of 374.69K. The stock’s Relative Strength Index (RSI) is 48.24, with weekly volatility at 7.76% and ATR at 0.35. The ADMS stock’s 52-week price range has touched low of $2.43 and a $9.15 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Adamas Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $212.79 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Adamas Pharmaceuticals Inc. (ADMS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For ADMS, the company has in raw cash 124.83 million on their books with 3.58 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 158.1 million total, with 29.18 million as their total liabilities.
Potential earnings growth for Adamas Pharmaceuticals Inc. (ADMS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Adamas Pharmaceuticals Inc. recorded a total of 19.31 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 25.01% coming in sequential stages and their sales for the 08/12/2021 quarter reducing by -8.8%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.39 million trying to sell their products during the last quarter, with the result yielding a gross income of 18.93 million. This allows shareholders to hold on to 35.17M with the recently reported earning now reading -0.36 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (-0.36 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.42 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ADMS sounds very interesting.
Is the stock of ADMS attractive?
In related news, Chief Commercial Officer, Shreedhar Vijay sold 1,051 shares of the company’s stock in a transaction that recorded on Mar 22. The sale was performed at an average price of 5.50, for a total value of 5,780. As the sale deal closes, the Chief Financial Officer, Prentiss Christopher B now sold 2,422 shares of the company’s stock, valued at 13,273. Also, Director, Papapetropoulos Spyridon bought 5,975 shares of the company’s stock in a deal that was recorded on Mar 11. The shares were price at an average price of 5.06 per share, with a total market value of 30,233. Following this completion of acquisition, the Chief Financial Officer, Prentiss Christopher B now holds 3,821 shares of the company’s stock, valued at 24,302. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.60%.
5 out of 8 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Adamas Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the ADMS stock. The 12-month mean consensus price target for the company’s shares has been set at $9.07.